

URGENT DRUG RECALL

Follow-up Communication to August 17, 2026, Urgent Drug Recall

August 25, 2026

Dear Healthcare Provider or Distributor:

On August 17, 2026, Baxter Healthcare Corporation issued an Urgent Drug Recall for one lot of 70% Dextrose Injection listed below due to the potential presence of particulate matter identified as stainless steel particles in the solution. The affected lot was distributed from 7/25/2026 to 7/28/2026 in the United States.

Update: Please note that Baxter has updated the 'Hazard Involved' section and product photos below.

Affected Product

Product Code	Product Description	Lot Number	Expiration Date	NDC Number
2B0296H	70% Dextrose Injection, USP in 2000 mL VIAFLEX Plastic Container. Pharmacy Bulk Package, Not for Direct Infusion.	Y495066	31-Jul-2027	0338-0719-06

Hazard Involved

Intravenous administration of 70% Dextrose Injection containing stainless steel particulate matter may lead to serious adverse health consequences. Particulate matter can cause blockage and clotting in blood vessels which can cut off blood flow to vital organs, lead to a life-threatening blood clot in the lungs (pulmonary embolism) and cause permanent organ damage or death. Additionally, these particles may cause local vein irritation, inflammatory reaction, aggravation of preexisting infections, and allergic reactions. To date, Baxter has not received any reports of adverse events related to this issue.

Actions to be Taken by Customers

1. Immediately locate, isolate, and cease all use of the affected lot number of the product. The product code, lot number, and expiration date can be found on the individual product and shipping carton. Please see the below product label photos to assist in identifying the product.



Container Label



Carton Label

2. Contact Baxter Healthcare Center for Service to arrange for return and replacement product at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday. Please have your Baxter 8-digit ship-to account number, product code, lot number, and quantity of product to be returned ready when calling.
3. If you received this communication directly from Baxter, please acknowledge receipt of this notification by following the instructions in the corresponding email, even if you have no remaining inventory. Acknowledging receipt will prevent you from receiving repeat notices. If you do not complete the acknowledgement, you will receive a phone call from Accenture LLP on behalf of Baxter to confirm your receipt of this notification.
4. If you purchased this product from a distributor or wholesaler, please contact them to arrange for return of the affected product. In this case, you do not need to respond to Baxter directly. If a response is requested by your distributor or wholesaler, please respond to them according to their instructions.
5. Please forward a copy of this communication to the director of pharmacy, director of nursing, director of purchasing, facility risk manager, and any other departments within your institution who use the affected product.
6. If you are a dealer, wholesaler, distributor/reseller, or original equipment manufacturer (OEM) that distributed any affected product to other facilities, please conduct a user-level recall of the affected product that you distributed to customers and check the associated box on the customer portal.

Further Information and Support

For general questions regarding this communication, please contact Baxter Healthcare Center for Service at 888-229-0001 between the hours of 7:00 am and 6:00 pm Central Time, Monday through Friday.

The United States Food and Drug Administration (FDA) has been notified of this action. Any product quality complaints or adverse events experienced with the use of these products may be reported using one of the following options:

- Contacting Baxter Product Surveillance at the Baxter product feedback portal at <https://productfeedback.baxter.com>, or emailing Baxter at corporate_product_complaints_round_lake@baxter.com
- Reporting to the FDA MedWatch Serious Injury Reporting Program:
 - o **Online:** By completing and submitting the report at www.accessdata.fda.gov/scripts/medwatch
 - o **Regular mail or Fax:** Download the form from www.fda.gov/MedWatch/getforms.htm or call 800-332-1088 to request a reporting form, then complete and mail it to the address on the pre-addressed form or submit by fax to 800-332-0178

Baxter is committed to patient safety and to providing safe, high-quality products. We apologize for any inconvenience this may cause you and your staff.

Sincerely,



Craig Plunkard
Senior Director, Quality
Baxter Healthcare Corporation